Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Clinical Oncology |
| Vol/bind | 26 |
| Udgave nummer | 18 |
| Sider (fra-til) | 3057-62 |
| Antal sider | 5 |
| ISSN | 0732-183X |
| DOI | |
| Status | Udgivet - 2008 |
Bibliografisk note
Keywords: Adult; Breast Neoplasms; Cell Cycle Proteins; DNA-Binding Proteins; Denmark; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Male; Middle Aged; Mutation, Missense; Neoplasms; Prospective Studies; Protein-Serine-Threonine Kinases; Tumor Suppressor ProteinsAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Risk of cancer by ATM missense mutations in the general population. / Dombernowsky, Sarah Louise; Weischer, Maren; Allin, Kristine Højgaard; Bojesen, Stig Egil; Tybjaerg-Hansen, Anne; Nordestgaard, Børge Grønne.
I: Journal of Clinical Oncology, Bind 26, Nr. 18, 2008, s. 3057-62.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Risk of cancer by ATM missense mutations in the general population
AU - Dombernowsky, Sarah Louise
AU - Weischer, Maren
AU - Allin, Kristine Højgaard
AU - Bojesen, Stig Egil
AU - Tybjaerg-Hansen, Anne
AU - Nordestgaard, Børge Grønne
N1 - Keywords: Adult; Breast Neoplasms; Cell Cycle Proteins; DNA-Binding Proteins; Denmark; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Male; Middle Aged; Mutation, Missense; Neoplasms; Prospective Studies; Protein-Serine-Threonine Kinases; Tumor Suppressor Proteins
PY - 2008
Y1 - 2008
N2 - PURPOSE: Truncating and missense mutations in the ATM gene, which cause insufficient DNA damage surveillance, allow damaged cells to proceed into mitosis, which eventually results in increased cancer susceptibility. We tested the hypotheses that ATM Ser49Cys and ATM Ser707Pro heterozygosity increase the risk of cancer overall, of breast cancer, and of 26 other cancer subtypes in the general population. PATIENTS AND METHODS: We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years, during which 2,056 developed cancer. RESULTS: Multifactorially adjusted hazard ratios for ATM Ser49Cys heterozygotes versus noncarriers were 1.2 (95% CI, 0.9 to 1.5) for cancer overall, 0.8 (95% CI, 0.3 to 2.0) for breast cancer, 4.8 (95% CI, 2.2 to 11) for melanoma, 2.3 (95% CI, 1.1 to 5.0) for prostate cancer, and 3.4 (95% CI, 1.1 to 11) for cancer of the oral cavity/pharynx. Multifactorially adjusted hazard ratios for ATM Ser707Pro heterozygotes versus noncarriers were 0.8 (95% CI, 0.6 to 1.2) for cancer overall, 0.6 (95% CI, 0.2 to 1.6) for breast cancer, 10 (95% CI, 1.1 to 93) for thyroid/other endocrine tumors, and 2.7 (95% CI, 1.0 to 7.6) for cancer of corpus uteri. CONCLUSION: ATM missense mutations do not increase the risk of cancer overall or of breast cancer in the general population; however, we observed in exploratory analyses that ATM missense mutations may be associated with an increased risk of other cancer subtypes. As we did multiple comparisons, some of these findings could represent chance findings rather than real phenomena.
AB - PURPOSE: Truncating and missense mutations in the ATM gene, which cause insufficient DNA damage surveillance, allow damaged cells to proceed into mitosis, which eventually results in increased cancer susceptibility. We tested the hypotheses that ATM Ser49Cys and ATM Ser707Pro heterozygosity increase the risk of cancer overall, of breast cancer, and of 26 other cancer subtypes in the general population. PATIENTS AND METHODS: We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years, during which 2,056 developed cancer. RESULTS: Multifactorially adjusted hazard ratios for ATM Ser49Cys heterozygotes versus noncarriers were 1.2 (95% CI, 0.9 to 1.5) for cancer overall, 0.8 (95% CI, 0.3 to 2.0) for breast cancer, 4.8 (95% CI, 2.2 to 11) for melanoma, 2.3 (95% CI, 1.1 to 5.0) for prostate cancer, and 3.4 (95% CI, 1.1 to 11) for cancer of the oral cavity/pharynx. Multifactorially adjusted hazard ratios for ATM Ser707Pro heterozygotes versus noncarriers were 0.8 (95% CI, 0.6 to 1.2) for cancer overall, 0.6 (95% CI, 0.2 to 1.6) for breast cancer, 10 (95% CI, 1.1 to 93) for thyroid/other endocrine tumors, and 2.7 (95% CI, 1.0 to 7.6) for cancer of corpus uteri. CONCLUSION: ATM missense mutations do not increase the risk of cancer overall or of breast cancer in the general population; however, we observed in exploratory analyses that ATM missense mutations may be associated with an increased risk of other cancer subtypes. As we did multiple comparisons, some of these findings could represent chance findings rather than real phenomena.
U2 - 10.1200/JCO.2007.14.6613
DO - 10.1200/JCO.2007.14.6613
M3 - Journal article
C2 - 18565893
VL - 26
SP - 3057
EP - 3062
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 18
ER -